Gameto, a NYC-based biotechnology company dedicated to advancing treatment options in women’s health, raised $33M in Series B funding.
The round, which brought the total amount to $73M, was led by Two Sigma Ventures and RA Capital with participation from existing investors, including Insight Partners, Future Ventures, and BOLD Capital Partners. The investor group was also joined by Olivia Walton’s Ingeborg Investments, Stacey Bendet Eisner, Founder, CEO, and Creative Director of alice + olivia, and Chelsea Hirschhorn, Founder and CEO of Frida.
The company intends to use the funds for the clinical development of Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) to mature eggs outside of the body.
Led by Dr. Dina Radenkovic, Chief Executive Officer, Gameto is a biotechnology company developing novel treatment solutions for women’s health, starting with infertility. Its lead program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body.
Following productive discussions with the U.S. Food and Drug Administration, Gameto received tentative approval to proceed to Phase 3 trials, subject to the completion of certain assay and manufacturing requirements. The funding will continue to support the commercial launches of Fertilo in Australia and Latin America where it is already being used in the clinic.
FinSMEs
29/05/2024